Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus chemoradiotherapy versus chemoradiotherapy alone for locally advanced cervical cancer
RBR-8mf5x2Phase 3Not yet recruiting
- Sponsor
- Eurofarma
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab in Cervical Cancer (CC) (2 arms), sponsored by Eurofarma. Planned start Jan 2014; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on RBR-8mf5x2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8mf5x2.